You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Ann Arbor, Michigan
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 10
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas on Tuesday, May 14, 2019 at 6:55 p.m. E.T. in Las Vegas on Tuesday, May 14, 2019 at 6:55 p.m. E.T. UBS Global Healthcare Conference in New York on Monday, May 20, 2019 at 9:30 a.m. E.T. A live audio webcast of the UBS event can be accessed on th...
Yahoo FinanceMay 9
Esperion Gets a Go-Ahead from the FDA
Esperion Therapeutics (ESPR) has reported that the FDA has accepted both New Drug Applications for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review, asserts John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
Expected Aug 1, Pre-Market